Figure S2 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Zhang, Hailei; Rutkowska, Anna; González-Martín, Antonio; Mirza, Mansoor R.; Monk, Bradley J.; Vergote, Ignace; Pothuri, Bhavana; Graybill, Whitney A. Spannuth; Goessel, Carsten; Barbash, Olena; Bergamini, Giovanna; Feng, Bin

doi:10.1158/2767-9764.28302680

Figure S2 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

https://doi.org/10.1158/2767-9764.28302680

journal contribution

posted on 2025-01-29, 10:00 authored by Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R. Mirza, Bradley J. Monk, Ignace Vergote, Bhavana Pothuri, Whitney A. Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng

<p>Retrospective analysis of PRIMA clinical trial in the HRd and HRp groups – stratified by patient characteristics (age and weight) and statin treatment (type of statin and its dose level)</p>

History

Related Materials

1.
DOI - Is supplement to Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

ARTICLE ABSTRACT

The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.

Usage metrics

Keywords

Clinical-stage Research Dna Repair Dna Damage And Repair Gynecological Cancers Ovarian Cancer

Licence

CC BY

Figure S2 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports